Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.710

+0.1%

12:12 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (701)	3/30/2007 12:03:01 PM
From: zeta1961	Read Replies (1) of 802

Unless they change the rules, INGN has been going thru CBER since this division was created..most likeley Advexin will go thru yesterday's panel(with some changes to include gene-therapy specific panel members) since this was the 'Cellular, Tissue and Gene Therapies Advisory Committee' fda.gov ..I'll do some digging to confirm..I listened to the last hour of yesterdays session after the DNDN vote and they spoke all about the agency's own research in immunology, viral vectors for gene therapy and other cell tissue work..nothing of note as they went into closed session for the 'juice'..current trials discussion. I don't know where Padzur will fit in DNDN or related decisions..we finally have a commissioner..the DNDN bulls think he's got a progressive approach but I don't know enuf to opinionate.. I will say that after watching yesterday's meeting, it felt like a breath of fresh air..science and common sense finding agreement..

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next